This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

UT Southwestern Names Frank Grassler As Vice President For Technology Development

DALLAS, Jan. 31, 2013 /PRNewswire-USNewswire/ -- UT Southwestern Medical Center announced that Frank Grassler has been appointed as Vice President for Technology Development, and will lead the Office of Technology Development as well as BioCenter at Southwestern Medical District.


The Office of Technology Development has been involved in creating six startup companies that have raised more than $500 million in venture capital. BioCenter is the university's commercial biomedical campus and encourages the development and commercialization of university-created technologies.

"Frank will be working with UT Southwestern faculty members as part of our commitment to promote the commercial development of their discoveries to the ultimate benefit of patients," said Dr. Daniel K. Podolsky, President of UT Southwestern. "He is widely respected for his integrity, judgment, expertise, and management skills."

Mr. Grassler comes to UT Southwestern after working as a consultant for Genentech Inc. From 2008 to 2011, he was Vice President for Intellectual Property at Gilead Sciences. Prior to that, he was Vice President of U.S. Intellectual Property for GlaxoSmithKline for 12 years. Earlier in his career, he was in private practice as an attorney and worked in patent law for Merck.

At GlaxoSmithKline, Mr. Grassler conceived the intellectual property structure of The SNP Consortium, originally comprising 10 pharmaceutical companies, a British philanthropic organization, and four academic research centers. Members of the consortium consented to share data and intellectual property rights for DNA sequence variations called single nucleotide polymorphisms, an agreement that lifted institutional and legal barriers and unleashed important work in drug discovery. He earned degrees in pharmacy and law from the University of Colorado, and did additional coursework in mechanical engineering, materials science, and immunology at the University of Colorado, Denver.

"Every day, UT Southwestern faculty members, researchers, and clinicians are working on groundbreaking discoveries and inventions," Mr. Grassler said. "We want to use the commercialization process to translate those discoveries into therapies that can benefit patients worldwide."

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs